Gilead Turns Back To Virology With $1.4bn MYR Acquisition

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.

Shopping cart on blue background
Gilead's 2020 deal-making spree now includes a drug for hepatitis D

Even without its noteworthy involvement in developing the antiviral Veklury to treat COVID-19 patients and subsequent manufacturing and distribution agreements, Gilead Sciences, Inc. has had a busy deal-making year in 2020, with a primary focus on cancer. But with its acquisition of MYR GmbH on 10 December, Gilead is returning to an earlier focus of its business development efforts by obtaining the first approved drug for the hepatitis D virus (HDV), a comorbidity of the more common hepatitis B.

Gilead agreed to buy the privately held biotech for €1.15bn (about $1.4bn) with a potential future milestone payment of €300m...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.